You Are Forging a New Tool in the Fight Against Pancreatic Cancer
Pancreatic cancer is one of the most dangerous cancers, largely because it’s so difficult to detect early. Thanks to research you help make possible, that may be about to change.
“One promising strategy to reduce the number of people affected by pancreatic cancer is to identify and treat premalignant pancreatic lesions,” says Dr. Jennifer Permuth-Wey, of Moffitt’s Department of Cancer Epidemiology. Dr. Permuth-Wey is part of a team of Moffitt researchers working to develop a blood test that can identify these lesions, known as IPMNs.
Identifying the type of IPMN will indicate whether there is a high or low risk of pancreatic cancer developing. But right now, the only way to perform an identification is to remove the lesion for study — a procedure which itself carries potentially severe health risks.
Teams at Moffitt are working on developing a fast, accurate blood test that can determine which IPMNs need to be surgically removed before they can develop into cancer, and which can be left alone and monitored.
This research holds great promise as a tool for catching pancreatic cancer early. It’s just one of the many ways you are taking the fight to cancer. Thank you for your generous support!